2-chloro-4-ethyl-5-nitropyridine | 101251-13-2

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 2-chloro-4-ethyl-5-nitropyridine
• CAS: 101251-13-2
• 化学式: C₇H₇ClN₂O₂
• mdl: MFCD12022594
• 分子量: 186.598
• InChiKey: UPCPWQBNVJOZLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  58.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-4-ethyl-5-nitropyridine 在 三乙基硅烷 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 N-碘代丁二酰亚胺 、 水 、 铁粉 、 氯化铵 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 25.0~80.0 ℃ 、344.75 kPa 条件下， 反应 30.0h， 生成 3-amino-6-chloro-4-ethylpicolinaldehyde
  参考文献：
  名称：

  WO2020117635A5

  摘要：

  公开号：

  WO2020117635A5
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 五氯化磷 、 三氯氧磷 作用下， 生成 2-chloro-4-ethyl-5-nitropyridine
  参考文献：
  名称：

  Catalytic Synthesis of Heterocycles.¹ X. Dehydrocyclization of 4-Ethyl-3-pyridinethiol to 6-Azathianaphthene

  摘要：

  DOI：

  10.1021/jo01106a028

文献信息

• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2017012647A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
• [EN] PYRROLOPYRIDAZINE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRROLOPYRIDAZINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：GOSSAMER BIOSERVICES INC

  公开号：WO2022109492A1

  公开（公告）日：2022-05-27

  Described herein are inhibitors of JAK kinases, pharmaceutical compositions comprising them, processes for preparing them and uses of such inhibitors to treat or prevent diseases, disorders and conditions associated with kinase function.

  本文描述了JAK激酶抑制剂，包括它们的制药组合物、制备它们的过程以及使用这些抑制剂来治疗或预防与激酶功能相关的疾病、紊乱和病况。
• NOVEL COMPOUND USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：GALAPAGOS NV

  公开号：US20140213576A1

  公开（公告）日：2014-07-31

  A novel compound according to Formula I, able to inhibit JAK as disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons.

  一种新的化合物按照公式I，能够抑制JAK，该化合物可以制备为药物组合物，并可用于哺乳动物包括人类的预防和治疗多种疾病，例如过敏或炎症性疾病、自身免疫疾病、增生性疾病、移植排斥、涉及软骨周转障碍的疾病、先天性软骨畸形和/或与IL6或干扰素的高分泌相关的疾病，举例而言。
• IRE1 SMALL MOLECULE INHIBITORS
  申请人：Cornell University

  公开号：EP3891137A1

  公开（公告）日：2021-10-13
• NOVEL ALKYLENE DERIVATIVES
  申请人：SHIONOGI & CO., LTD.

  公开号：US20160257641A1

  公开（公告）日：2016-09-08

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I): wherein R 1 is substituted or unsubstituted fused aromatic heterocyclyl etc., ring A is substituted or unsubstituted non-aromatic carbocycle etc., -L 1 - is —O—(CR 6 R 7 )m- etc., -L 2 - is —O—(CR 6 R 7 )n- etc., each R 6 and R 7 are independently hydrogen, halogen etc., R 2 is substituted or unsubstituted alkyl, R 3 is hydrogen or substituted or unsubstituted alkyl, R 4 is substituted or unsubstituted alkylcarbonyl etc.